Abstract
α2-Adrenergic receptors (α2-ARs) respond to norepinephrine and epinephrine to mediate diverse physiological effects. Using in situ hybridization, the expression pattern of the mRNA encoding the three α2-AR subtypes (α2A, α2B, and α2C) was examined in the mouse embryo. The mRNA encoding the three subtypes was first detected at stage 9.5 days postcoitus (d.p.c.) for the α2A-AR (coincident with norepinephrine availability), 11.5 d.p.c. for the α2B-AR, and 14.5 d.p.c. for the α2C-AR subtype. The mRNA encoding the α2A-AR subtype shows both the earliest and the most widespread expression pattern, including developing stomach and cecum, many craniofacial regions and areas in the central nervous system. Strikingly, the α2A-AR mRNA is expressed in the interdigital mesenchyme between stage 12.5 and 14.5 d.p.c. in parallel with digit separation, raising the possibility that the α2A-AR might contribute to the apoptotic events underlying this process. To test whether α2A-AR can signal apoptotic events, the α2A-AR subtype was introduced into two mouse mesenchymal cell lines, C3H/10t½ and NIH-3T3; expression of the α2A-AR correlated with accelerated apoptosis, as detected both by the TUNEL assay and the loss of cell viability. In contrast to the wide distribution of mRNA encoding the α2A-AR subtype, the α2B-AR mRNA was detected only in the developing liver and was most readily detectable between 11.5 and 14.5 d.p.c., when the liver is the principal site of hematopoiesis. The α2C-AR mRNA is detected in the nasal cavity and cerebellar primordium only at ≥14.5 d.p.c. These studies represent the first characterization of the temporal and spatial expressions of the α2A-AR, α2B-AR, and α2C-AR subtypes during embryogenesis and provide important insights concerning the loci and possible roles of α2-AR-mediated regulation of physiological processes during the developmental program.
Footnotes
- Received June 27, 1997.
- Accepted August 11, 1997.
-
Send reprint requests to: Lee E. Limbird, Ph.D., Department of Pharmacology, Vanderbilt University Medical Center, 476 MRB I, Nashville, Tennessee 37232-6600. E-mail:lee.limbird{at}mcmail.vanderbilt.edu
-
↵1 Current affiliation: BC Cancer Research Center, Vancouver, British Columbia, Canada, V5V 1L3.
-
This work was supported by National Institutes of Health Grant HL43671.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|